Updated: Multiple Biosimilars To Avastin Have Launched In EU
Industry Had Expected June Roll-Out
Executive Summary
Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.
You may also be interested in...
What’s Next? Five Things To Look Out For In August
Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.
Amgen Takes Almost 40% Of US Bevacizumab Market
Amgen’s biosimilar revenues were more than $350m in the second quarter of this year, as the company benefitted from the ‘innovator product’ commercialization model across its increasingly broad portfolio of biosimilars.
Oncology Aids Pfizer As Biosimilars Track To $1bn In 2020
Pfizer is on course for a major milestone for biosimilars this year, as it continues to make plans for the separation of its off-patent and mature brands unit, Upjohn, ahead of its merger with Mylan.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: